Concurrent alcohol dependence among methadone-maintained cocaine abusers is associated with greater abstinence
- PMID: 21463068
- PMCID: PMC3072227
- DOI: 10.1037/a0022795
Concurrent alcohol dependence among methadone-maintained cocaine abusers is associated with greater abstinence
Abstract
Concurrent alcohol dependence (AD) among polysubstance abusers has been associated with negative consequences, although it may not necessarily lead to poor treatment outcomes. One of the most efficacious treatments for cocaine abuse is contingency management (CM), but little research has explored the impact of AD on abstinence outcomes, particularly among patients in methadone maintenance. Using data from three trials of CM for cocaine use, we compared baseline characteristics and posttreatment and follow-up cocaine outcomes between methadone-maintained, cocaine-dependent patients (N = 193) with and without concurrent AD, randomized to standard care (SC) with or without CM. Patients with and without concurrent AD had similar baseline characteristics, with the exception that AD patients reported more alcohol use. AD patients achieved longer durations of cocaine abstinence and were more likely to submit a cocaine-negative sample at follow-up than non-AD patients. Patients randomized to CM achieved better outcomes than those randomized to SC, but there was no interaction between treatment condition and AD status. These findings suggest that cocaine-using methadone patients with AD achieve greater cocaine abstinence than their non-AD counterparts and should not necessarily be viewed as more difficult to treat.
Figures


Similar articles
-
Cocaine abusers with and without alcohol dependence respond equally well to contingency management treatments.Exp Clin Psychopharmacol. 2008 Aug;16(4):275-81. doi: 10.1037/a0012787. Exp Clin Psychopharmacol. 2008. PMID: 18729681 Free PMC article.
-
Older methadone patients achieve greater durations of cocaine abstinence with contingency management than younger patients.Am J Addict. 2013 Mar-Apr;22(2):119-26. doi: 10.1111/j.1521-0391.2013.00306.x. Epub 2013 Feb 1. Am J Addict. 2013. PMID: 23414496 Free PMC article. Clinical Trial.
-
Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone.Arch Gen Psychiatry. 1999 Sep;56(9):812-20. doi: 10.1001/archpsyc.56.9.812. Arch Gen Psychiatry. 1999. PMID: 12884887 Clinical Trial.
-
Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial.Drug Alcohol Depend. 2014 Jul 1;140:92-100. doi: 10.1016/j.drugalcdep.2014.03.033. Epub 2014 Apr 16. Drug Alcohol Depend. 2014. PMID: 24814607 Free PMC article. Clinical Trial.
-
Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials.Am J Drug Alcohol Abuse. 2009;35(5):339-49. doi: 10.1080/00952990903108215. Am J Drug Alcohol Abuse. 2009. PMID: 20180662
Cited by
-
Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users.Cochrane Database Syst Rev. 2018 Dec 5;12(12):CD009269. doi: 10.1002/14651858.CD009269.pub4. Cochrane Database Syst Rev. 2018. PMID: 30521696 Free PMC article.
-
Identifying provider beliefs related to contingency management adoption using the contingency management beliefs questionnaire.Drug Alcohol Depend. 2012 Mar 1;121(3):205-12. doi: 10.1016/j.drugalcdep.2011.08.027. Epub 2011 Sep 16. Drug Alcohol Depend. 2012. PMID: 21925807 Free PMC article.
-
Longitudinal effects of interoceptive awareness training through mindful awareness in body-oriented therapy (MABT) as an adjunct to women's substance use disorder treatment: A randomized controlled trial.Drug Alcohol Depend. 2019 May 1;198:140-149. doi: 10.1016/j.drugalcdep.2019.02.012. Epub 2019 Mar 23. Drug Alcohol Depend. 2019. PMID: 30928884 Free PMC article. Clinical Trial.
-
Implementing an evidence-based prize contingency management protocol for stimulant use.J Subst Use Addict Treat. 2023 Aug;151:209079. doi: 10.1016/j.josat.2023.209079. Epub 2023 May 24. J Subst Use Addict Treat. 2023. PMID: 37230390 Free PMC article.
-
Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: a randomized clinical trial.JAMA Psychiatry. 2014 May;71(5):547-56. doi: 10.1001/jamapsychiatry.2013.4546. JAMA Psychiatry. 2014. PMID: 24647726 Free PMC article. Clinical Trial.
References
-
- Alterman AI, Kampman K, Boardman CR, Rutherford MJ, McKay JR, Maany I. A cocaine-positive baseline urine predicts outpatient treatment attrition and failure to attain initial abstinence. Drug and Alcohol Dependence. 1997;46:79–85. - PubMed
-
- Alterman AI, McKay JR, Mulvaney FD, Cnaan A, Cacciola JS, Tourian KA, et al. Baseline prediction of 7-month cocaine abstinence for cocaine dependency patients. Drug and Alcohol Dependence. 2000;59:215–221. - PubMed
-
- Bunney EB, Appel SB, Brodie MS. Electrophysiological effects of cocaethylene, cocaine, and ethanol on dopaminergic neurons of the ventral tegmental area. The Journal of Pharmacology and Experimental Therapeutics. 2001;297:696–703. - PubMed
-
- Carroll KM, Rounsaville BJ, Bryant KJ. Alcoholism in treatment-seeking cocaine abusers: Clinical and prognostic significance. Journal of Studies on Alcohol. 1993;54:199–208. - PubMed
-
- Chatham LR, Rowan-Szal GA, Joe GW, Brown BS, Simpson DD. Heavy drinking in a population of methadone-maintained clients. Journal of Studies on Alcohol. 1995;56:417–422. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 DA013444/DA/NIDA NIH HHS/United States
- P30-DA023918/DA/NIDA NIH HHS/United States
- T32-AA07290/AA/NIAAA NIH HHS/United States
- R01-DA024667/DA/NIDA NIH HHS/United States
- P50 DA009241/DA/NIDA NIH HHS/United States
- R01 DA021567/DA/NIDA NIH HHS/United States
- R01 DA024667/DA/NIDA NIH HHS/United States
- M01 RR006192/RR/NCRR NIH HHS/United States
- R01-DA021567/DA/NIDA NIH HHS/United States
- R01-DA022739/DA/NIDA NIH HHS/United States
- P60 AA003510/AA/NIAAA NIH HHS/United States
- R01-DA016855/DA/NIDA NIH HHS/United States
- R01-DA027615/DA/NIDA NIH HHS/United States
- R01-DA13444/DA/NIDA NIH HHS/United States
- R01 DA027615/DA/NIDA NIH HHS/United States
- R01-DA018883/DA/NIDA NIH HHS/United States
- R21-DA021836/DA/NIDA NIH HHS/United States
- R01 DA014618/DA/NIDA NIH HHS/United States
- R01 DA022739/DA/NIDA NIH HHS/United States
- M01-RR06192/RR/NCRR NIH HHS/United States
- T32 AA007290/AA/NIAAA NIH HHS/United States
- R01 DA018883/DA/NIDA NIH HHS/United States
- R01 DA016855/DA/NIDA NIH HHS/United States
- R21 DA021836/DA/NIDA NIH HHS/United States
- R01-DA14618/DA/NIDA NIH HHS/United States
- P60-AA03510/AA/NIAAA NIH HHS/United States
- P30 DA023918/DA/NIDA NIH HHS/United States
- P50-DA09241/DA/NIDA NIH HHS/United States